기도양압 기기 시장 : 시장 규모, 점유율, 동향 분석(제품별, 용도별, 최종 용도별, 지역별), 부문별 예측(2026-2033년)

Positive Airway Pressure Devices Market Summary

The global positive airway pressure devices market size was valued at USD 4.82 billion in 2025 and is projected to reach USD 7.40 billion by 2033, growing at a CAGR of 5.48% from 2026 to 2033. This growth is attributed to the increasing prevalence of sleep apnea, advancements in technology, rising awareness and diagnosis of sleep disorders, and improving healthcare infrastructure.

These factors are fueling the demand for PAP devices globally. Growing health concerns, better diagnostic methods, and technological innovations are shaping the market's future growth prospects. Sleep apnea, particularly OSA, has become increasingly common worldwide. The growing prevalence of obesity is a major contributor to the increasing number of sleep apnea cases. Obesity is strongly linked to OSA as excess fat around the neck can obstruct airflow during sleep, leading to interrupted breathing. Sleep apnea cases have seen a sharp increase in regions where obesity rates are high (e.g., the U.S. & Europe). Obesity is a major risk factor for sleep apnea, with up to 40% of obese people also suffering from OSA in the UK. According to an article by the Sleep Apnea Trust in 2023, up to 10 million people in the UK suffer from OSA, of whom around 4 million suffer from moderate or severe OSA. Thus, the increasing prevalence of respiratory diseases in the country is expected to fuel the market over the forecast period. In addition, according to a study published in the Journal of Pulmonary Therapy in July 2022, the most common respiratory symptoms, such as shortness of breath and active cough, affect over 17% of adult citizens.

The advanced healthcare infrastructure and high investment in R&D in the U.S. have enabled manufacturers to develop & launch the latest technologies in respiratory devices, making them more efficient, portable, & user-friendly. In January 2022, Cathay Capital made a strategic investment in CPAP.com to support expansion and strengthen its position in the sleep apnea treatment market. The move reflects rising demand for CPAP and PAP devices as obstructive sleep apnea continues to grow significantly due to aging demographics and increasing obesity rates

Rising awareness and diagnosis of sleep disorders are crucial factors propelling market growth. As people become more educated about sleep apnea and its potential risks, they are more likely to seek diagnosis and treatment. Public health campaigns run by organizations such as the American Sleep Apnea Association helped improve awareness. In addition, improved diagnostic methods such as polysomnography and home sleep tests have made identifying sleep apnea in its early stages easier. The increasing recognition of sleep apnea as a significant health concern drives more individuals to pursue PAP therapy, thus fueling market demand.

Global Positive Airway Pressure Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global positive airway pressure devices market report based on product, application, end use, and region.

• Product Outlook (Volume, 000' Units; Revenue, USD Million, 2021 - 2033)
• CPAP
  • Connected
  • Bluetooth-Connected CPAP
  • Wi-Fi & Cellular Connected CPAP
  • Hybrid-Connected
  • Non-Connected
• APAP
• Bi-PAP
• Application Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
• Obstructive Sleep Apnea
• Respiratory Failures
• COPD
• End Use Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
• Home Care Settings
• Hospitals & Clinics
• Others (Long-Term Care Facilities, etc.)
• Regional Outlook (Volume, 000'Units; Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Denmark
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. End Use Outlook
  • 2.2.4. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Positive Airway Pressure Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Incidence of Obstructive Sleep Apnea (OSA)
    • 3.2.1.2. Technological advancements
    • 3.2.1.3. Supportive Initiatives by Government and Private Organizations for PAP Devices
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Product Recalls and Device Failures
    • 3.2.2.2. Patient discomfort and compliance issues
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Positive Airway Pressure Devices Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's Five Forces
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal Landscape
• 3.4. Regulatory Overview
• 3.5. Technology overview (current products vs. next-gen features)
• 3.6. Major Deals & Strategic Alliances Analysis in the Positive Airway Pressure Devices

Chapter 4. Positive Airway Pressure Devices Market: Product Estimates & Trend Analysis

• 4.1. Definition and Scope
• 4.2. Product Market Share Analysis, 2025 & 2033
• 4.3. Segment Dashboard
• 4.4. Positive Airway Pressure Devices Market: By Product, 2021 to 2033
  • 4.4.1. CPAP
    • 4.4.1.1. CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 4.4.1.2. Connected
      • 4.4.1.2.1. Connected Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
      • 4.4.1.2.2. Bluetooth-Connected CPAP
        • 4.4.1.2.2.1. Bluetooth Connected CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
      • 4.4.1.2.3. Wi-Fi & Cellular Connected CPAP
        • 4.4.1.2.3.1. Wi Fi & Cellular Connected CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
      • 4.4.1.2.4. Hybrid-Connected
        • 4.4.1.2.4.1. Hybrid Connected CPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
    • 4.4.1.3. Non-Connected
      • 4.4.1.3.1. Non- Connected Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 4.4.2. APAP
    • 4.4.2.1. APAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 4.4.3. BiPAP
    • 4.4.3.1. BiPAP Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 5. Positive Airway Pressure Devices Market: Application Estimates & Trend Analysis

• 5.1. Definition and Scope
• 5.2. Application Market Share Analysis, 2025 & 2033
• 5.3. Segment Dashboard
• 5.4. Positive Airway Pressure Devices Market: By Application, 2021 to 2033
  • 5.4.1. Obstructive Sleep Apnea
    • 5.4.1.1. Obstructive Sleep Apnea Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 5.4.2. Respiratory Failures
    • 5.4.2.1. Respiratory Failures Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 5.4.3. COPD
    • 5.4.3.1. COPD Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 6. Positive Airway Pressure Devices Market: End Use Estimates & Trend Analysis

• 6.1. Definition and Scope
• 6.2. End Use Market Share Analysis, 2025 & 2033
• 6.3. Segment Dashboard
• 6.4. Positive Airway Pressure Devices Market: By End Use, 2021 to 2033
  • 6.4.1. Hospitals and Clinics
    • 6.4.1.1. Hospitals and Clinics Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 6.4.2. Home Care Settings
    • 6.4.2.1. Home Care Settings Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units
  • 6.4.3. Others (Long-Term Care Facilities, etc.)
    • 6.4.3.1. Others (Long-Term Care Facilities, etc.) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million) (000') Units

Chapter 7. Positive Airway Pressure Devices Market: Regional Estimates & Trend Analysis by Region, Product, Application, End Use

• 7.1. Regional Dashboard
• 7.2. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework
    • 7.3.1.3. Reimbursement Scenario
    • 7.3.1.4. Competitive scenario
    • 7.3.1.5. U.S. market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework
    • 7.3.2.3. Reimbursement Scenario
    • 7.3.2.4. Competitive scenario
    • 7.3.2.5. Canada market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework
    • 7.3.3.3. Reimbursement Scenario
    • 7.3.3.4. Competitive scenario
    • 7.3.3.5. Mexico market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework
    • 7.4.1.3. Reimbursement Scenario
    • 7.4.1.4. Competitive scenario
    • 7.4.1.5. UK market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework
    • 7.4.2.3. Reimbursement Scenario
    • 7.4.2.4. Competitive scenario
    • 7.4.2.5. Germany market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework
    • 7.4.3.3. Reimbursement Scenario
    • 7.4.3.4. Competitive scenario
    • 7.4.3.5. France market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework
    • 7.4.4.3. Reimbursement Scenario
    • 7.4.4.4. Competitive scenario
    • 7.4.4.5. Italy market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework
    • 7.4.5.3. Reimbursement Scenario
    • 7.4.5.4. Competitive scenario
    • 7.4.5.5. Spain market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.6. Denmark
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework
    • 7.4.6.3. Reimbursement Scenario
    • 7.4.6.4. Competitive scenario
    • 7.4.6.5. Denmark market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework
    • 7.4.7.3. Reimbursement Scenario
    • 7.4.7.4. Competitive scenario
    • 7.4.7.5. Sweden market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.4.8. Norway
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework
    • 7.4.8.3. Reimbursement Scenario
    • 7.4.8.4. Competitive scenario
    • 7.4.8.5. Norway market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework
    • 7.5.1.3. Reimbursement Scenario
    • 7.5.1.4. Competitive scenario
    • 7.5.1.5. Japan market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Reimbursement Scenario
    • 7.5.2.4. Competitive scenario
    • 7.5.2.5. China market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Reimbursement Scenario
    • 7.5.3.4. Competitive scenario
    • 7.5.3.5. India market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5.4. South Korea
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Reimbursement Scenario
    • 7.5.4.4. Competitive scenario
    • 7.5.4.5. South Korea market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5.5. Thailand
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework
    • 7.5.5.3. Reimbursement Scenario
    • 7.5.5.4. Competitive scenario
    • 7.5.5.5. Thailand market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.5.6. Australia
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework
    • 7.5.6.3. Reimbursement Scenario
    • 7.5.6.4. Competitive scenario
    • 7.5.6.5. Australia market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework
    • 7.6.1.3. Reimbursement Scenario
    • 7.6.1.4. Competitive scenario
    • 7.6.1.5. Brazil market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Reimbursement Scenario
    • 7.6.2.4. Competitive scenario
    • 7.6.2.5. Argentina market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework
    • 7.7.1.3. Reimbursement Scenario
    • 7.7.1.4. Competitive scenario
    • 7.7.1.5. South Africa market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Reimbursement Scenario
    • 7.7.2.4. Competitive scenario
    • 7.7.2.5. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Reimbursement Scenario
    • 7.7.3.4. Competitive scenario
    • 7.7.3.5. UAE market estimates and forecasts 2021 to 2033 (USD Million) (000') Units
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Reimbursement Scenario
    • 7.7.4.4. Competitive scenario
    • 7.7.4.5. Kuwait market estimates and forecasts 2021 to 2033 (USD Million) (000') Units

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis, 2025
• 8.3. Company Market Share Analysis, CPAP Devices, 2025
• 8.4. Company Market Share Analysis, APAP Devices, 2025
• 8.5. Company Market Share Analysis, Bi-PAP Devices, 2025
• 8.6. Company Categorization
• 8.7. Company Profiles/Listing
  • 8.7.1. Koninklijke Philips N.V.
    • 8.7.1.1. Participant's Overview
    • 8.7.1.2. Financial Performance
    • 8.7.1.3. Product Benchmarking
    • 8.7.1.4. Strategy Mapping
  • 8.7.2. Fisher & Paykel Healthcare Limited
    • 8.7.2.1. Participant's Overview
    • 8.7.2.2. Financial Performance
    • 8.7.2.3. Product Benchmarking
    • 8.7.2.4. Strategy Mapping
  • 8.7.3. ResMed
    • 8.7.3.1. Participant's Overview
    • 8.7.3.2. Financial Performance
    • 8.7.3.3. Product Benchmarking
    • 8.7.3.4. Strategy Mapping
  • 8.7.4. Drive DeVilbiss Healthcare
    • 8.7.4.1. Participant's Overview
    • 8.7.4.2. Financial Performance
    • 8.7.4.3. Product Benchmarking
    • 8.7.4.4. Strategy Mapping
  • 8.7.5. React Health (3B Medical)
    • 8.7.5.1. Participant's Overview
    • 8.7.5.2. Financial Performance
    • 8.7.5.3. Product Benchmarking
    • 8.7.5.4. Strategy Mapping
  • 8.7.6. BMC Medical
    • 8.7.6.1. Participant's Overview
    • 8.7.6.2. Financial Performance
    • 8.7.6.3. Product Benchmarking
    • 8.7.6.4. Strategy Mapping
  • 8.7.7. Armstrong Medical Inc.
    • 8.7.7.1. Participant's Overview
    • 8.7.7.2. Financial Performance
    • 8.7.7.3. Product Benchmarking
    • 8.7.7.4. Strategy Mapping
  • 8.7.8. Wellell (Apex Medical)
    • 8.7.8.1. Participant's Overview
    • 8.7.8.2. Financial Performance
    • 8.7.8.3. Product Benchmarking
    • 8.7.8.4. Strategy Mapping
  • 8.7.9. Breas Medical
    • 8.7.9.1. Participant's Overview
    • 8.7.9.2. Financial Performance
    • 8.7.9.3. Product Benchmarking
    • 8.7.9.4. Strategy Mapping
  • 8.7.10. SEFAM
    • 8.7.10.1. Participant's Overview
    • 8.7.10.2. Financial Performance
    • 8.7.10.3. Product Benchmarking
    • 8.7.10.4. Strategy Mapping
  • 8.7.11. Trudell Medical (Vyaire)
    • 8.7.11.1. Participant's Overview
    • 8.7.11.2. Financial Performance
    • 8.7.11.3. Product Benchmarking
    • 8.7.11.4. Strategy Mapping
  • 8.7.12. Lowenstein Medical UK Ltd
    • 8.7.12.1. Participant's Overview
    • 8.7.12.2. Financial Performance
    • 8.7.12.3. Product Benchmarking
    • 8.7.12.4. Strategy Mapping
  • 8.7.13. Transcend Inc. (Somnetics International, Inc.)
    • 8.7.13.1. Participant's Overview
    • 8.7.13.2. Financial Performance
    • 8.7.13.3. Product Benchmarking
    • 8.7.13.4. Strategy Mapping